XML 67 R58.htm IDEA: XBRL DOCUMENT v3.21.1
Shareholders' Equity - Schedule of Components of Shareholder's Equity (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Beginning Balance $ 33,483 $ 30,838
Net loss (3,919) (7,732)
Stock-based compensation 1,290 937
Sale of common shares, including at-the-market transactions 71,746 7,597
Financing costs paid to issue common shares, including at-the-market transactions (2,878) (1)
Exercise of stock options 348  
Exercise of warrants 802  
Shares issued upon vesting of RSU, net of shares retired to pay employees' taxes   (14)
Issuance of common stock to Razor Genomics and Insight Genetics acquisition 5,756 5,000
Ending Balance 106,628 36,625
Common Stock [Member]    
Beginning Balance $ 157,160 $ 124,583
Beginning Balance, shares 69,117 57,032
Net loss
Stock-based compensation 1,290 937
Sale of common shares, including at-the-market transactions $ 71,746 $ 7,597
Sale of common shares, including at-the-market transactions, shares 18,427 3,523
Financing costs paid to issue common shares, including at-the-market transactions $ (2,878) $ (1)
Exercise of stock options $ 348  
Exercise of stock options, shares 140  
Exercise of warrants $ 802  
Exercise of warrants, shares 248  
Shares issued upon vesting of RSU, net of shares retired to pay employees' taxes   $ (14)
Shares issued upon vesting of RSU, net of shares retired to pay employees' taxes, shares   13
Issuance of common stock to Razor Genomics and Insight Genetics acquisition $ 5,756 $ 5,000
Issuance of common stock to Razor Genomics and Insight Genetics acquisition, shares 982 1,916
Ending Balance $ 234,224 $ 138,102
Ending Balance, shares 88,914 62,484
Accumulated Other Comprehensive Loss [Member]    
Beginning Balance
Net loss
Stock-based compensation
Sale of common shares, including at-the-market transactions
Financing costs paid to issue common shares, including at-the-market transactions
Exercise of stock options  
Exercise of warrants  
Shares issued upon vesting of RSU, net of shares retired to pay employees' taxes  
Issuance of common stock to Razor Genomics and Insight Genetics acquisition
Ending Balance
Accumulated Deficit [Member]    
Beginning Balance (123,677) (93,745)
Net loss (3,919) (7,732)
Stock-based compensation
Sale of common shares, including at-the-market transactions
Financing costs paid to issue common shares, including at-the-market transactions
Exercise of stock options  
Exercise of warrants  
Shares issued upon vesting of RSU, net of shares retired to pay employees' taxes  
Issuance of common stock to Razor Genomics and Insight Genetics acquisition
Ending Balance $ (127,596) $ (101,477)